JP2009532467A - 安定化ペントサンポリサルフェート(pps)製剤およびその分析方法 - Google Patents
安定化ペントサンポリサルフェート(pps)製剤およびその分析方法 Download PDFInfo
- Publication number
- JP2009532467A JP2009532467A JP2009504229A JP2009504229A JP2009532467A JP 2009532467 A JP2009532467 A JP 2009532467A JP 2009504229 A JP2009504229 A JP 2009504229A JP 2009504229 A JP2009504229 A JP 2009504229A JP 2009532467 A JP2009532467 A JP 2009532467A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- pps
- concentration
- dosage form
- bell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 270
- 238000009472 formulation Methods 0.000 title claims abstract description 256
- 229940043138 pentosan polysulfate Drugs 0.000 title claims abstract description 235
- 238000004458 analytical method Methods 0.000 title claims description 21
- 238000001962 electrophoresis Methods 0.000 claims abstract description 101
- 241000124008 Mammalia Species 0.000 claims abstract description 35
- 230000001954 sterilising effect Effects 0.000 claims abstract description 35
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 33
- 230000015556 catabolic process Effects 0.000 claims abstract description 29
- 238000006731 degradation reaction Methods 0.000 claims abstract description 29
- 208000005615 Interstitial Cystitis Diseases 0.000 claims abstract description 7
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 60
- 239000002552 dosage form Substances 0.000 claims description 58
- 238000005251 capillar electrophoresis Methods 0.000 claims description 53
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- 239000000872 buffer Substances 0.000 claims description 35
- 239000007857 degradation product Substances 0.000 claims description 27
- 238000010521 absorption reaction Methods 0.000 claims description 26
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 25
- 229920001542 oligosaccharide Polymers 0.000 claims description 25
- 150000002482 oligosaccharides Chemical class 0.000 claims description 25
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 20
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000012669 liquid formulation Substances 0.000 claims description 15
- 238000005057 refrigeration Methods 0.000 claims description 15
- 150000002337 glycosamines Chemical class 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 10
- 239000001509 sodium citrate Substances 0.000 claims description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 7
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 230000010354 integration Effects 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000001034 Frostbite Diseases 0.000 claims description 5
- 206010018852 Haematoma Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical group Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 3
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 3
- 229940040102 levulinic acid Drugs 0.000 claims description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims 6
- 235000006708 antioxidants Nutrition 0.000 claims 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 235000021317 phosphate Nutrition 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 235000010378 sodium ascorbate Nutrition 0.000 claims 2
- 229960005055 sodium ascorbate Drugs 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002845 discoloration Methods 0.000 abstract description 8
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 17
- 238000010586 diagram Methods 0.000 description 16
- 238000012494 forced degradation Methods 0.000 description 16
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 15
- 238000005259 measurement Methods 0.000 description 13
- 238000000354 decomposition reaction Methods 0.000 description 12
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 9
- 238000005515 capillary zone electrophoresis Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 238000005370 electroosmosis Methods 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 239000004280 Sodium formate Substances 0.000 description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 3
- 235000019254 sodium formate Nutrition 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 230000019635 sulfation Effects 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- JCSJTDYCNQHPRJ-MMDFAQQLSA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-beta-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)OC2)O)OC1 JCSJTDYCNQHPRJ-MMDFAQQLSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 208000010544 human prion disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 238000012503 pharmacopoeial method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 2
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000009662 stress testing Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000007693 zone electrophoresis Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000012495 forced degradation study Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】 図14
Description
ペントサンポリサルフェート(pentosan polysulfate)(PPS)は、多価陰イオン性多糖の混合物を含む、半合成ポリ硫酸化オリゴ糖である。PPSは、木本、例えばブナから得られる多糖(例えばキシラン)の化学的硫酸化により生成される。生じる生成物は、典型的には分子量約4000〜10000と推定される多分散ポリマー分子の混合物中に糖残基1個あたり約1.5〜1.9個の共有結合硫酸基の形態で約15〜17%の硫黄を含有するものである。PPSは、β−D−キシロピラノース1〜4個が結合したユニットが約12から30個の硫酸化直鎖多糖からなり(Mr=約4000〜約10000)、約10ユニット毎にD−グルコン酸を有する。PPSは、典型的には植物性物質から半合成的に製造されるが、微生物から得ることもできる。
Claims (83)
- ペントサンポリサルフェート(PPS)を含む液体製剤であって、冷蔵せずに安定な製剤。
- 約4から約8の範囲のpHを有する溶液中で冷蔵せずに安定である、請求項1に記載の製剤。
- ペントサンポリサルフェートから本質的になるオリゴ糖を含む液体製剤であって、冷蔵せずに安定な製剤。
- 冷蔵せずに約1年間安定である、請求項1に記載の製剤。
- 冷蔵せずに約3年間安定である、請求項1に記載の製剤。
- 冷蔵せずに約5年間安定である、請求項1に記載の製剤。
- 約7から約8の範囲のpHを有する溶液中で冷蔵せずに安定である、請求項1に記載の製剤。
- PPSの分解産物が実質的にない、請求項1に記載の製剤。
- 前記製剤の最終滅菌が、前記製剤の色に実質的に影響しない、請求項1に記載の製剤。
- 最終滅菌後に前記製剤が冷蔵せずに安定である、請求項1に記載の製剤。
- 最終滅菌後にPPSの分解産物が実質的にない、請求項1に記載の製剤。
- 前記製剤の最終滅菌後に、前記製剤中の前記PPSが実質的に均一の分子量を有する、請求項1に記載の製剤。
- 約25mg/mLから約500mg/mLの濃度のPPSを含む、請求項1に記載の製剤。
- キレーター、緩衝剤、抗酸化剤、および抗菌剤のうち少なくとも1つをさらに含む、請求項1に記載の製剤。
- メタ重亜硫酸塩、亜硫酸水素ナトリウム、およびアスコルビン酸塩からなる群から選択される抗酸化剤をさらに含み、前記抗酸化剤が、前記製剤の約0.02%w/vから約5%w/vの濃度で存在する、請求項1に記載の製剤。
- メチルパラベン、プロピルパラベン、およびベンジルアルコールからなる群から選択される抗菌剤をさらに含み、前記抗菌剤が、前記製剤の約0.05%w/vから約0.2%w/vの濃度で存在する、請求項1に記載の製剤。
- 約1mg/mLの濃度でメチルパラベンをさらに含む、請求項1に記載の製剤。
- 約0.1mMから約1mMの濃度でEDTAをさらに含む、請求項1に記載の製剤。
- 前記PPSが、約25mg/mLから約500mg/mLの濃度で存在し、前記製剤が、
約1mMから約100mMの濃度のクエン酸ナトリウム、または
約1mMから約100mMの濃度のクエン酸
をさらに含む、請求項1に記載の製剤。 - 約0.1mMから約1mMの濃度のEDTAをさらに含む、請求項19に記載の製剤。
- 約1mMから約100mMの濃度で存在する緩衝剤をさらに含む、請求項1に記載の製剤。
- さらに緩衝剤を含む請求項1に記載の製剤であって、前記緩衝剤は、クエン酸塩、水酸化ナトリウム/レブリン酸、酢酸塩、重炭酸塩、亜硫酸水素塩、水酸化ナトリウム/グリシン、およびリン酸塩のうち少なくとも1つを含む、前記の製剤。
- さらに緩衝剤を含む請求項1に記載の製剤であって、前記緩衝剤が、製剤中で約1から約100mMの濃度のクエン酸ナトリウムを含む、請求項1に記載の製剤。
- クエン酸を含む緩衝剤をさらに含む、請求項1に記載の製剤。
- 亜硫酸水素ナトリウムをさらに含む、請求項1に記載の製剤。
- 前記亜硫酸水素ナトリウムが、最大約10mg/mLの濃度で存在する、請求項25に記載の製剤。
- アミノ糖をさらに含む、請求項1に記載の製剤。
- 前記アミノ糖が、グルコサミン塩酸塩、ガラクトサミン、グルコサミンサルフェート、グルコサミンホスフェート、N−アセチルグルコサミン、マンノサミン、その混合物または塩からなる群から選択される、請求項27に記載の製剤。
- ヒアルロン酸をさらに含む、請求項1に記載の製剤。
- ペントサンポリサルフェート(PPS)を含む液体製剤の試料中におけるサルフェート以外の分解産物を検出する方法であって:
前記試料を最終滅菌すること;および
サルフェート以外の1つまたは複数の分解産物を前記試料中において検出するためにキャピラリー電気泳動を用いること;
を含む方法。 - 最終滅菌することが、オートクレーブすることを含む、請求項30に記載の方法。
- ペントサンポリサルフェート(PPS)を含む液体注射用剤形であって、冷蔵せずに安定な剤形。
- 約10mgから約5グラムのPPSを含む、請求項32に記載の剤形。
- 約10mgから約5gのアミノ糖を含む、請求項32に記載の剤形。
- 約0.1mgから約3gのヒアルロン酸を含む、請求項32に記載の剤形。
- 薬学的に許容できる担体を含む、請求項32に記載の剤形。
- 前記PPSが、約25mg/mLから約500mg/mLのPPS濃度で存在する、請求項32に記載の剤形。
- キレーター、緩衝剤、抗酸化剤、および抗菌剤のうち少なくとも1つをさらに含む、請求項32に記載の剤形。
- メタ重亜硫酸塩、亜硫酸水素ナトリウム、およびアスコルビン酸塩からなる群から選択される抗酸化剤をさらに含む剤形であって、前記抗酸化剤が、前記剤形の約0.02%w/vから約5%w/vの濃度で存在する、請求項32に記載の剤形。
- メチルパラベン、プロピルパラベン、およびベンジルアルコールからなる群から選択される抗菌剤をさらに含む剤形であって、前記抗菌剤が、前記剤形の約0.05%w/vから約0.2%w/vの濃度で存在する、請求項32に記載の剤形。
- 約1mg/mLの濃度のメチルパラベンをさらに含む、請求項32に記載の剤形。
- 約0.1mMから約1mMの濃度のEDTAをさらに含む、請求項32に記載の剤形。
- 約1mMから約100mMの濃度のクエン酸ナトリウム、または
約1mMから約100mMの濃度のクエン酸
をさらに含む、請求項37に記載の剤形。 - 約0.1mMから約1mMの濃度のEDTAをさらに含む、請求項43に記載の剤形。
- 約1mMから約100mMの濃度で存在する緩衝剤をさらに含む、請求項32に記載の剤形。
- クエン酸塩、水酸化ナトリウム/レブリン酸、酢酸塩、重炭酸塩、亜硫酸水素塩、水酸化ナトリウム/グリシン、およびリン酸塩のうち少なくとも1つを含む緩衝剤をさらに含む、請求項32に記載の剤形。
- 製剤中にクエン酸ナトリウムを約1から約100mMの濃度で含む緩衝剤をさらに含む、請求項32に記載の剤形。
- クエン酸を含む緩衝剤をさらに含む、請求項32に記載の剤形。
- 亜硫酸水素ナトリウムをさらに含む、請求項32に記載の剤形。
- 前記亜硫酸水素ナトリウムが、最大約10mg/mLの濃度で存在する、請求項49に記載の剤形。
- 前記アミノ糖が、グルコサミン塩酸塩、ガラクトサミン、グルコサミンサルフェート、グルコサミンホスフェート、N−アセチルグルコサミン、マンノサミン、およびその混合物または塩からなる群から選択される、請求項34に記載の剤形。
- 前記アミノ糖が、約25mg/mLから約500mg/mLの濃度で存在する、請求項34に記載の剤形。
- 前記ヒアルロン酸が、約0.1mg/mLから約50mg/mLの濃度で存在する、請求項35に記載の剤形。
- 約250mg/mLの濃度のペントサンポリサルフェート(PPS)、
最大約20mg/mLの濃度の亜硫酸水素ナトリウム、および
約0.25mg/mLの濃度のEDTA
を含む注射用剤形であって、製剤が、約6から約7のpH範囲で冷蔵せずに安定な剤形。 - 約250mg/mLの濃度のペントサンポリサルフェート(PPS)、
最大約10mg/mLの濃度の亜硫酸水素ナトリウム、
約0.25mg/mLの濃度のEDTA、および
約1mg/mLの濃度のメチルパラベン
を含む注射用剤形であって、製剤が、約5.8から約6.2のpH範囲で冷蔵せずに安定な剤形。 - 約250mg/mLの濃度のペントサンポリサルフェート(PPS)、
最大約10mg/mLの濃度の亜硫酸水素ナトリウム、
約0.25mg/mLの濃度のEDTA、および
約1mg/mLの濃度のメチルパラベン
を含む注射用剤形であって、製剤が、約7.8から約8.2のpH範囲で冷蔵せずに安定な剤形。 - 再構成後に請求項32から56のいずれか一項に記載の剤形を含むように製剤化された凍結乾燥剤形。
- 請求項32から56のいずれか一項に記載の剤形を凍結乾燥することによって製剤化された凍結乾燥剤形。
- 哺乳動物において、骨関節炎、間質性膀胱炎、感染性海綿状脳症(TSE)、免疫不全ウイルス(HIV/AIDSまたはFIVなど)、血腫、痔、凍傷、火傷、血栓症、またはアテローム性動脈硬化症からなる群から選択される疾患を治療する方法であって、前記哺乳動物に前記疾患を治療するための有効量の、請求項1、3、および14のいずれかに記載の液体製剤を経口投与することを含む方法。
- 哺乳動物において、骨関節炎、間質性膀胱炎、感染性海綿状脳症(TSE)、免疫不全ウイルス(HIV/AIDSまたはFIVなど)、血腫、痔、凍傷、火傷、血栓症、またはアテローム性動脈硬化症からなる群から選択される疾患を治療する方法であって、前記哺乳動物に前記疾患を治療するための有効量の、請求項32、38、および54から56のいずれかに記載の剤形を注射することを含む方法。
- 前記液体製剤を1日約1回または1週間に約2回投与することを含む、請求項59に記載の方法。
- 前記剤形を1週間に約1回注射することを含む、請求項60に記載の方法。
- 前記哺乳動物に前記液体製剤を1日約1回、約1〜3カ月間投与すること、次いで前記哺乳動物に前記液体製剤を投与することを約1〜3カ月間やめること、および次いで前記哺乳動物に前記液体製剤を1日約1回、約1〜3カ月間投与することを含む、請求項59に記載の方法。
- 前記哺乳動物に前記剤形を1週間に約1回約1〜3カ月間注射すること、次いで前記哺乳動物に前記剤形を注射することを約1〜3カ月間やめること、および次いで前記哺乳動物に前記剤形を1週間に約1回約1〜3カ月間注射することを含む、請求項60に記載の方法。
- 前記量の前記液体製剤が、各投与において約4mg/kgから約20mg/kgの経口濃度のPPSを送達するために十分な量を含む、請求項59に記載の方法。
- 前記量の前記剤形が、各注射において約1mg/kgから約5mg/kgのPPSを注射するために十分な量を含む、請求項60に記載の方法。
- 哺乳動物において骨関節炎を治療する方法であって、前記哺乳動物に請求項1、3、および14のいずれか一項に記載の液体製剤を経口投与することを含む方法。
- 前記投与することが、前記哺乳動物に前記液体製剤を1日に約1回投与することを含む、請求項67に記載の方法。
- 前記投与することが、前記哺乳動物に前記液体製剤を1日に約1回、約4から約5週間投与することを含む、請求項67に記載の方法。
- 哺乳動物において骨関節炎を治療する方法であって、前記哺乳動物に請求項32、38、および54から56のいずれか一項に記載の剤形を注射することを含む方法。
- 前記注射することが、前記哺乳動物に前記剤形を1週間に約1回注射することを含む、請求項70に記載の方法。
- 前記注射することが、前記哺乳動物に前記剤形を1週間に約1回、約4から約5週間注射することを含む、請求項71に記載の方法。
- キャピラリー電気泳動を用いてペントサンポリサルフェート(PPS)製剤の安定性の指標を検出する方法であって、
前記製剤の試料を水中で約1から約5mg/mLの濃度に調製すること、
ピーク分解能基準を満たすように、キャピラリー電気泳動を用いて前記製剤について電気泳動図であって、時間に対する吸収変化のグラフを含む電気泳動図を用意すること、
実質的にベルを定義し、PPSに対応する、前記電気泳動図の実質的なベル形部分を確認すること、および
谷から谷までの積分によって決定されるサイズ特性であって、1つまたは複数のピークのサイズ特性に比べた前記ベルのサイズ特性に基づいて、前記製剤の安定性の指標を決定すること
を含む方法。 - 前記安定性の指標が、以下のものからなる群から選択される、請求項73に記載の方法:
前記ベルの面積が、前記1つまたは複数のピークの総和面積の少なくとも約13倍であること;
前記ベルの高さが、ペントサン均一性基準を満たす任意のピークの高さの約3倍超であること;および
前記ベルの前記高さが、3番目に高いピークの約4倍超であること。 - 前記試料を調製する前に、前記製剤を分解促進条件に供することをさらに含む、請求項73に記載の方法。
- 前記製剤がペントサン均一性基準を満たすことを判定することをさらに含む、請求項75に記載の方法。
- 前記分解促進条件が、時間の経過を含む、請求項75に記載の方法。
- 前記分解促進条件が、室温よりも著しく高い温度を含む、請求項75に記載の方法。
- ペントサンポリサルフェート(PPS)を含む液体製剤であって、約1mg/mLから約5mg/mLの試料濃度での前記製剤のキャピラリー電気泳動分析が、時間に対する吸収変化のグラフにおいてPPSの存在に対応する実質的なベル形曲線を示し、前記ベル形曲線が、初期吸収に対応する第1の部分および後期吸収に対応する第2の部分を含み、前記第1の部分および前記第2の部分がピーク中央部分で連結し、前記曲線の実質的なベル形部分内部の面積が、前記実質的なベル形曲線の前記第1の部分に出現するすべての別個のピークにより定義される合計面積の約10倍超であり、ここで面積が谷から谷への積分によって決定される製剤。
- 前記キャピラリー電気泳動分析がピーク分解能基準を満たす、請求項79に記載の製剤。
- 前記ベル形曲線が、ペントサン均一性基準を満たす、請求項79に記載の製剤。
- 前記製剤が、約4から約8のpH範囲を有する溶液中で冷蔵せずに安定である、請求項79に記載の製剤。
- ギ酸塩参照ピークの立ち下がり縁から測定される、前記実質的なベル形曲線内部の面積が、前記実質的なベル形曲線内部の合計面積の少なくとも50%を含む、請求項79に記載の製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78805206P | 2006-04-03 | 2006-04-03 | |
US60/788,052 | 2006-04-03 | ||
PCT/US2007/008066 WO2007123800A2 (en) | 2006-04-03 | 2007-04-03 | Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009532467A true JP2009532467A (ja) | 2009-09-10 |
JP5433881B2 JP5433881B2 (ja) | 2014-03-05 |
Family
ID=38625506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009504229A Active JP5433881B2 (ja) | 2006-04-03 | 2007-04-03 | 安定化ペントサンポリサルフェート(pps)製剤 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20070243218A1 (ja) |
EP (1) | EP2010220B1 (ja) |
JP (1) | JP5433881B2 (ja) |
AU (1) | AU2007240993B2 (ja) |
CA (1) | CA2648578A1 (ja) |
DK (1) | DK2010220T3 (ja) |
ES (1) | ES2913483T3 (ja) |
HU (1) | HUE058709T2 (ja) |
NZ (1) | NZ571537A (ja) |
PL (1) | PL2010220T3 (ja) |
PT (1) | PT2010220T (ja) |
WO (1) | WO2007123800A2 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015523151A (ja) * | 2012-07-13 | 2015-08-13 | ラボラトワール・ウルゴ | 有効成分を持続的に放出するドレッシング材 |
WO2019054344A1 (ja) | 2017-09-12 | 2019-03-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン及びポリ硫酸ペントサンの製造方法 |
WO2019124363A1 (ja) | 2017-12-20 | 2019-06-27 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬 |
WO2019151287A1 (ja) * | 2018-01-31 | 2019-08-08 | マルホ株式会社 | 皮膚外用組成物 |
WO2020039480A1 (ja) * | 2018-08-20 | 2020-02-27 | 株式会社レクメド | 新規ポリ硫酸ペントサンナトリウム製剤 |
US11274165B2 (en) | 2017-02-28 | 2022-03-15 | Oji Holdings Corporation | Pentosan polysulfate, pharmaceutical composition, and anticoagulant |
US11278485B2 (en) | 2017-05-31 | 2022-03-22 | Oji Holdings Corporation | Moisturizing topical preparation |
US11286272B2 (en) | 2016-08-31 | 2022-03-29 | Oji Holdings Corporation | Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide |
US11312790B2 (en) | 2016-08-31 | 2022-04-26 | Oji Holdings Corporation | Production method for pentosan polysulfate |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
AU2008100730B4 (en) * | 2008-07-04 | 2008-10-02 | Parnell Technologies Pty Ltd | Sulfated polysaccharide compound for clinical use and the preparation thereof |
AU2013202633B2 (en) * | 2008-07-04 | 2015-10-22 | Parnell Technologies Pty Ltd | A sulfated polysaccharide compound and the preparation and use thereof |
JP2012528830A (ja) * | 2009-06-04 | 2012-11-15 | アルク アーゲー | 少なくとも1つのアドレナリン作動性化合物を含む安定化された組成物 |
WO2011088418A2 (en) * | 2010-01-15 | 2011-07-21 | Mount Sinai School Of Medicine | Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
US8716204B2 (en) | 2010-07-27 | 2014-05-06 | Zimmer, Inc. | Synthetic synovial fluid compositions and methods for making the same |
WO2012027797A1 (en) * | 2010-09-02 | 2012-03-08 | David Charles James | Anti-inflammatory compostion |
WO2013054866A1 (ja) * | 2011-10-13 | 2013-04-18 | 国立大学法人 長崎大学 | Htlv-i関連脊髄症の予防または治療剤 |
WO2013116366A1 (en) * | 2012-01-30 | 2013-08-08 | Baxter International Inc. | Non-anticoagulant sulfated or sulfonated polysaccharides |
WO2014127418A1 (en) * | 2013-02-20 | 2014-08-28 | The University Of Queensland | Conjugate compound and uses of same |
MY179756A (en) | 2013-10-03 | 2020-11-12 | Dow Pharmaceutical Sciences | Stabilized efinaconazole formulations |
JP6611014B2 (ja) | 2013-11-22 | 2019-11-27 | ボシュ ヘルス アイルランド リミテッド | 抗感染方法、抗感染組成物、および抗感染装置 |
WO2016170158A1 (en) * | 2015-04-24 | 2016-10-27 | Bene Pharmachem Gmbh & Co. Kg | Method of detecting and/or quantifying pentosan polysulfate sodium |
AU2016267264A1 (en) * | 2015-05-27 | 2017-12-07 | Vanguard Therapeutics, Inc. | Pentosan polysulfate sodium for the treatment of sickle cell disease |
GB201616838D0 (en) * | 2016-10-04 | 2016-11-16 | Nat Univ Ireland | Hyaluronan compositions, and uses thereof in treatment of interstitial cystitis |
WO2018213629A1 (en) * | 2017-05-18 | 2018-11-22 | Adamis Pharmaceuticals Corporation | Drug compositions |
EP3586851A1 (en) * | 2018-06-27 | 2020-01-01 | Nextraresearch S.r.l. | Compositions for oral administration of pentosan polysulfate and chitosan in form of nanoparticles with improved intestinal absorption |
WO2021050320A1 (en) * | 2019-09-09 | 2021-03-18 | Harrow Ip, Llc | Pharmaceutical compositions comprising heparinoids and methods for preparing thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02188525A (ja) * | 1988-11-01 | 1990-07-24 | Baker Cummins Pharmaceut Inc | 間質性膀胱炎に対する治療用医薬組成物 |
WO2004091623A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals. Inc. | Pharmaceutical formulations containing methylnaltrexone |
WO2005037266A1 (en) * | 2003-10-08 | 2005-04-28 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenylacetic acid |
WO2005065649A1 (en) * | 2003-12-31 | 2005-07-21 | Cydex, Inc. | Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1327354C (en) * | 1987-03-19 | 1994-03-01 | David Cullis-Hill | Anti-inflamatory compounds and compositions |
US5668116A (en) * | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
US5643892A (en) * | 1995-06-07 | 1997-07-01 | Baker Norton Pharmaceuticals, Inc. | Method of treating chronic progressive vascular diseases |
US6255295B1 (en) * | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
AU2001230994A1 (en) * | 2000-01-19 | 2001-07-31 | The United States of America, represented by The Secretary, Department of Health & Human Services | Use of pentosan polysulfate to treat certain conditions of the prostate |
US6607745B2 (en) * | 2001-05-18 | 2003-08-19 | Harry Leneau | Ingestion of hyaluronic acid for improved joint function and health |
US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
-
2007
- 2007-04-03 PT PT77545713T patent/PT2010220T/pt unknown
- 2007-04-03 DK DK07754571.3T patent/DK2010220T3/da active
- 2007-04-03 ES ES07754571T patent/ES2913483T3/es active Active
- 2007-04-03 AU AU2007240993A patent/AU2007240993B2/en active Active
- 2007-04-03 JP JP2009504229A patent/JP5433881B2/ja active Active
- 2007-04-03 NZ NZ571537A patent/NZ571537A/en unknown
- 2007-04-03 WO PCT/US2007/008066 patent/WO2007123800A2/en active Application Filing
- 2007-04-03 CA CA002648578A patent/CA2648578A1/en not_active Abandoned
- 2007-04-03 PL PL07754571.3T patent/PL2010220T3/pl unknown
- 2007-04-03 EP EP07754571.3A patent/EP2010220B1/en active Active
- 2007-04-03 HU HUE07754571A patent/HUE058709T2/hu unknown
- 2007-04-03 US US11/730,742 patent/US20070243218A1/en not_active Abandoned
-
2011
- 2011-02-28 US US13/036,995 patent/US20110212914A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02188525A (ja) * | 1988-11-01 | 1990-07-24 | Baker Cummins Pharmaceut Inc | 間質性膀胱炎に対する治療用医薬組成物 |
WO2004091623A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals. Inc. | Pharmaceutical formulations containing methylnaltrexone |
JP2006522818A (ja) * | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | メチルナルトレキソンを含む医薬処方物 |
WO2005037266A1 (en) * | 2003-10-08 | 2005-04-28 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenylacetic acid |
JP2007508263A (ja) * | 2003-10-08 | 2007-04-05 | ノバルティス アクチエンゲゼルシャフト | 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む薬学的組成物 |
WO2005065649A1 (en) * | 2003-12-31 | 2005-07-21 | Cydex, Inc. | Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid |
JP2007517069A (ja) * | 2003-12-31 | 2007-06-28 | サイデックス・インコーポレイテッド | スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤 |
Non-Patent Citations (1)
Title |
---|
JPN6012034697; SCULLY,M.F. et al: 'The antiheparin effect of a heparinoid, pentosan polysulphate. Investigation of a mechanism' Biochem J Vol.218, No.3, 1984, p.657-65 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015523151A (ja) * | 2012-07-13 | 2015-08-13 | ラボラトワール・ウルゴ | 有効成分を持続的に放出するドレッシング材 |
US11312790B2 (en) | 2016-08-31 | 2022-04-26 | Oji Holdings Corporation | Production method for pentosan polysulfate |
US11286272B2 (en) | 2016-08-31 | 2022-03-29 | Oji Holdings Corporation | Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide |
US11274165B2 (en) | 2017-02-28 | 2022-03-15 | Oji Holdings Corporation | Pentosan polysulfate, pharmaceutical composition, and anticoagulant |
US11278485B2 (en) | 2017-05-31 | 2022-03-22 | Oji Holdings Corporation | Moisturizing topical preparation |
WO2019054344A1 (ja) | 2017-09-12 | 2019-03-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン及びポリ硫酸ペントサンの製造方法 |
US11390693B2 (en) | 2017-09-12 | 2022-07-19 | Oji Holdings Corporation | Pentosan polysulfate and method for producing pentosan polysulfate |
KR20200051688A (ko) | 2017-09-12 | 2020-05-13 | 오지 홀딩스 가부시키가이샤 | 폴리황산펜토산 및 폴리황산펜토산의 제조 방법 |
KR20200099533A (ko) | 2017-12-20 | 2020-08-24 | 오지 홀딩스 가부시키가이샤 | 폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약 |
US11344570B2 (en) | 2017-12-20 | 2022-05-31 | Oji Holdings Corporation | Pentosan polysulfate and medicine containing pentosan polysulfate |
WO2019124363A1 (ja) | 2017-12-20 | 2019-06-27 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬 |
WO2019151287A1 (ja) * | 2018-01-31 | 2019-08-08 | マルホ株式会社 | 皮膚外用組成物 |
WO2020039480A1 (ja) * | 2018-08-20 | 2020-02-27 | 株式会社レクメド | 新規ポリ硫酸ペントサンナトリウム製剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2648578A1 (en) | 2007-11-01 |
DK2010220T3 (da) | 2022-05-23 |
ES2913483T3 (es) | 2022-06-02 |
JP5433881B2 (ja) | 2014-03-05 |
WO2007123800A2 (en) | 2007-11-01 |
US20070243218A1 (en) | 2007-10-18 |
NZ571537A (en) | 2012-06-29 |
AU2007240993A1 (en) | 2007-11-01 |
EP2010220A4 (en) | 2013-05-01 |
WO2007123800A3 (en) | 2007-12-21 |
HUE058709T2 (hu) | 2022-09-28 |
PT2010220T (pt) | 2022-05-20 |
US20110212914A1 (en) | 2011-09-01 |
PL2010220T4 (pl) | 2022-08-16 |
EP2010220A2 (en) | 2009-01-07 |
EP2010220B1 (en) | 2022-02-16 |
PL2010220T3 (pl) | 2022-08-16 |
AU2007240993B2 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5433881B2 (ja) | 安定化ペントサンポリサルフェート(pps)製剤 | |
Volpi | Analytical aspects of pharmaceutical grade chondroitin sulfates | |
Keire et al. | Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches | |
Fu et al. | Heparin stability by determining unsubstituted amino groups using hydrophilic interaction chromatography mass spectrometry | |
Václavíková et al. | Isotachophoretic determination of glucosamine and chondroitin sulphate in dietary supplements. | |
TWI737229B (zh) | 製劑的製造方法、製劑製造的管理方法及製劑的檢查方法 | |
JP6157464B2 (ja) | 非抗凝固性硫酸化多糖の経口製剤を改善するための添加剤としての吸収促進剤 | |
TWI594757B (zh) | 製劑的製造方法、管理方法及檢查方法 | |
Volpi et al. | Structural definition of terrestrial chondroitin sulfate of various origin and repeatability of the production process | |
US20240168035A1 (en) | Methods for quantifying drug concentration in a prodrug composition | |
Sharkawi et al. | Chromatographic analysis of bromhexine and oxytetracycline residues in milk as a drug analysis medium with greenness profile appraisal | |
CN105136697A (zh) | 一种地塞米松磷酸钠注射液中间体检验方法 | |
Jaques et al. | Variation in commercial heparin and its relation to the problem of heparin standardization for clinical use | |
AU2014242354B2 (en) | Resorption enhancers as additives to improve the oral formulation of low molecular weight heparins | |
Laurent et al. | Fate of exogenous hyaluronic acid in the middle ear | |
Warttinger et al. | Quantification of heparin in complex matrices (including urine) using a mix-and-read fluorescence assay | |
JP7361256B2 (ja) | コンドロイチン硫酸の分析法 | |
CN116355113A (zh) | 一种去除热原的方法 | |
Holt et al. | Mucopolysaccharides in synovial fluid. Effect of aspirin and indomethacin on hyaluronic acid. | |
CN105769776A (zh) | 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法 | |
RU2605385C2 (ru) | Способ получения моноконъюгата полисиаловой кислоты с тимозином бета 4 и ковалентный моноконъюгат полисиаловой кислоты с тимозином бета 4, устойчивый к деградации в токе крови | |
CN117362468A (zh) | 一种鱼鳔硫酸软骨素-硫酸皮肤素杂合链及其制备方法与应用 | |
SU1439476A1 (ru) | Способ определени гексозаминов в медицинских препаратах | |
Rothenhöfer | Analytical approaches to the study of hyaluronan and hyaluronidases: Development and application of hyphenated chromatographic and electrophoretic methods | |
CN106596784A (zh) | 泰妙菌素中有关物质的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121003 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121011 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131001 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131030 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131106 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5433881 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |